Eli Lilly

#AbbVie #ABPI #Clinical trials #Eli Lilly #Life sciences #Pharmaceutical industry #Pharmaceuticals #UK #UK government

Pharma firms pull out of UK drug pricing agreement

AbbVie and Eli Lilly have left the voluntary medicines pricing agreement in protest over what they describe as “increasingly punitive revenue clawbacks”.  The companies have left the UK’s Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), a long-standing agreement between government and industry with roots going back to the… Read More

#Business & Investment #News #Trending News

#Boehringer Ingelheim #Cancer research #Collaboration #Diabetes #Drug development #Drug discovery #Eli Lilly #HIV #Lung cancer #Neurodevelopmental disorders #Precision medicine #Rare disease

DDW Highlights podcast shares five new stories

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news.  ‘Teamwork makes the dream work’ this week, with the launch of… Read More

#News

#Boehringer Ingelheim #Cancer research #Collaboration #Diabetes #Drug development #Drug discovery #Eli Lilly #HIV #Lung cancer #Neurodevelopmental disorders #Precision medicine #Rare disease

This week in drug discovery (5-9 December)

News round-up for 5-9 December by DDW Digital Content Editor Diana Spencer. ‘Teamwork makes the dream work’ this week, with the launch of new partnerships to further the development of precision drugs in neurodevelopmental disorders, lung cancer and rare paediatric diseases. The benefits of collaboration have also been… Read More

#News

Boy tests his blood sugar levels at home
#Boehringer Ingelheim #Eli Lilly #Paediatrics #Phase III trial #Type 2 diabetes

Positive Phase III trial data for SGLT2 inhibitor in type 2 diabetes

A Phase III trial has demonstrated that Jardiance (empagliflozin) is the first SGLT2 inhibitor to show a reduction in blood sugar levels in children and adolescents with type 2 diabetes.  The DINAMO Phase III clinical trial demonstrated a statistically significant reduction in HbA1c with empagliflozin compared with… Read More

#News

Mammography
#Breast cancer #Eli Lilly #Oncology

UK’s NICE recommends Eli Lilly’s breast cancer drug  

Early breast cancer patients in England will be able to access a new form of treatment following the recommendation for Eli Lilly’s abemaciclib by the National Institute of Health and Care Excellence (NICE).  The approval means that abemaciclib will be able to be used in combination with… Read More

#News

#Eli Lilly #MHRA #Oncology #Regulatory

MHRA approves Eli Lilly’s breast cancer oral inhibitor  

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to Eli Lilly’s oral inhibitor abemaciclib for the treatment of patients with a specific type of breast cancer.   Abemaciclib will now be able to be used in combination with endocrine therapy for the adjuvant treatment… Read More

#News